ClinicalTrials.gov

A service of the U.S. National Institutes of Health

Trial record **1 of 1** for: CR013879

Previous Study | Return to List | Next Study

RESTART C0168Z05 Rheumatoid Arthritis Study

This study has been completed.

Sponsor:
Centocor Ortho Biotech Services, L.L.C.

Collaborator:
Schering-Plough

Information provided by (Responsible Party):
Centocor Ortho Biotech Services, L.L.C.

ClinicalTrials.gov Identifier:
NCT00714493

First received: July 10, 2008
Last updated: August 29, 2013
Last verified: August 2013
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Results First Received: January 14, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Rheumatoid Arthritis

Intervention:	Biological: Infliximab

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Infliximab	Infliximab 3 mg/kg (intravenously) at weeks 0,2,6; Increase to 5 mg/kg (i.v.) or 7 mg/kg (i.v.) based on EULAR response

Participant Flow: Overall Study

	Infliximab
STARTED	**203**
COMPLETED	**154**
NOT COMPLETED	**49**
Adverse Event	**11**
Death	**3**

Lack of Efficacy	**10**
Lost to Follow-up	**3**
Protocol Violation	**12**
SUBJECT CHOICE (SUBJECT WITHDREW CONSENT	**8**
OTHER	**2**

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab	Infliximab 3 mg/kg (intravenously) at weeks 0,2,6; Increase to 5 mg/kg (i.v.) or 7 mg/kg (i.v.) based on EULAR response

Baseline Measures

	Infliximab
Number of Participants [units: participants]	**203**
Age [units: participants]	

<=18 years	**0**
Between 18 and 65 years	**171**
>=65 years	**32**
Age [units: years] Mean (Standard Deviation)	**54 (12.07)**
Gender [units: participants]	
Female	**161**
Male	**42**
Region of Enrollment [units: participants]	
Europe	**43**
North America	**160**

Outcome Measures

Hide All Outcome Measures

1. Primary: Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 [Time Frame: Week 10]

Measure Type	Primary
Measure Title	Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10
Measure Description	Percent of patients who achieved EULAR response at Week 10. EULAR response is defined based on the DAS28

	score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.
Time Frame	Week 10
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The evaluable population was the subset of the mITT population (included the enrolled patients who received at least 1 dose of study medication) after excluding all 6 patients from Site 8631 where significant trial misconducts were identified.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed [units: participants]	**197**
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 [units: Percentage]	**49.7**

No statistical analysis provided for Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10

2. Secondary: Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase [Time Frame: Week 26]

Measure Type	Secondary
Measure Title	Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase
Measure Description	Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase
Time Frame	Week 26
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed [units: participants]	**197**
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab	

Dose Increase [units: percentage]	**22.3**

No statistical analysis provided for Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase

3. Secondary: Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26 [Time Frame: Week 26]

Measure Type	Secondary
Measure Title	Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26
Measure Description	Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26
Time Frame	Week 26
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed [units: participants]	**197**
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26 [units: percentage]	**51.8**

No statistical analysis provided for Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26

4. Secondary: Change From Baseline in Physical Function (HAQ) [Time Frame: Week 10]

Measure Type	Secondary
Measure Title	Change From Baseline in Physical Function (HAQ)
Measure Description	Change from baseline in physical function (HAQ) at Week 10. HAQ assesses the degree of difficulty a person has in accomplishing tasks. A lower HAQ score indicates less difficulty. Change from baseline is computed as Week 10 value minus baseline value. A negative value in change from baseline indicates an improvement.
Time Frame	Week 10
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed [units: participants]	**173**
Change From Baseline in Physical Function (HAQ) [units: scale -3 to 3] Mean (Standard Deviation)	**-0.173 (0.4548)**

Statistical Analysis 1 for Change From Baseline in Physical Function (HAQ)

Groups [1]	Infliximab 3 mg/kg
Method [2]	Wilcoxon signed rank test
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical

	significance:
	No text entered.

5. Secondary: Change From Baseline in Physical Function (HAQ) [Time Frame: Week 26]

Measure Type	Secondary
Measure Title	Change From Baseline in Physical Function (HAQ)
Measure Description	Change from baseline in physical function (HAQ) at Week 26. HAQ assesses the degree of difficulty a person has in accomplishing tasks. A lower HAQ score indicates less difficulty. Change from baseline is computed as Week 26 value minus baseline value. A negative value in change from baseline indicates an improvement.
Time Frame	Week 26
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg

Number of Participants Analyzed [units: participants]	**151**
Change From Baseline in Physical Function (HAQ) [units: scale -3 to 3] Mean (Standard Deviation)	**-0.223 (0.4968)**

Statistical Analysis 1 for Change From Baseline in Physical Function (HAQ)

Groups [1]	Infliximab 3 mg/kg
Method [2]	Wilcoxon signed rank test
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

6. Secondary: Percent of Patients Who Achieved ACR20 at Week 10 [Time Frame: Week 10]

Measure Type	Secondary
Measure Title	Percent of Patients Who Achieved ACR20 at Week 10

Measure Description	Percent of patients who achieved ACR20 at Week 10. A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
Time Frame	Week 10
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed [units: participants]	**197**
Percent of Patients Who Achieved ACR20 at Week 10 [units: percentage]	**28.4**

No statistical analysis provided for Percent of Patients Who Achieved ACR20 at Week 10

7. Secondary: Percent of Patients Who Achieved ACR20 at Weeks 26. [Time Frame: Week 26]

Measure Type	Secondary
Measure Title	Percent of Patients Who Achieved ACR20 at Weeks 26.
Measure Description	Percent of patients who achieved ACR20 at Weeks 26. A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
Time Frame	Week 26
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Infliximab 3 mg/kg	Infliximab 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Measured Values

	Infliximab 3 mg/kg
Number of Participants Analyzed	

[units: participants]	**197**
Percent of Patients Who Achieved ACR20 at Weeks 26. [units: percentage]	**35.5**

No statistical analysis provided for Percent of Patients Who Achieved ACR20 at Weeks 26.

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	All untoward events occurring between the time of obtaining informed consent through Week 30 or early termination were collected, regardless of causality.
Additional Description	No text entered.

Reporting Groups

	Description
Infliximab	Infliximab 3 mg/kg (intravenously) at weeks 0,2,6; Increase to 5 mg/kg (i.v.) or 7 mg/kg (i.v.) based on EULAR response

Serious Adverse Events

	Infliximab
Total, serious adverse events	
# participants affected / at risk	**10/203 (4.93%)**
Blood and lymphatic system disorders	
Anaemia * 1	

# participants affected / at risk	1/203 (0.49%)
Cardiac disorders	
Cardiac Failure Congestive * 1	
# participants affected / at risk	2/203 (0.99%)
Acute Myocardial Infarction * 1	
# participants affected / at risk	1/203 (0.49%)
Atrial Fibrillation * 1	
# participants affected / at risk	1/203 (0.49%)
Atrioventricular Block Complete * 1	
# participants affected / at risk	1/203 (0.49%)
Cardiac Failure * 1	
# participants affected / at risk	1/203 (0.49%)
Cardiogenic Shock * 1	
# participants affected / at risk	1/203 (0.49%)
Congestive Cardiomyopathy * 1	
# participants affected / at risk	1/203 (0.49%)
Myocardial Infarction * 1	
# participants affected / at risk	1/203 (0.49%)
General disorders	
Multi-Organ Failure * 1	
# participants affected / at risk	1/203 (0.49%)
Immune system disorders	
Hypersensitivity * 1	

# participants affected / at risk	**1/203 (0.49%)**
Infections and infestations	
Erysipelas * 1	
# participants affected / at risk	**1/203 (0.49%)**
Metabolism and nutrition disorders	
Diabetes Mellitus * 1	
# participants affected / at risk	**1/203 (0.49%)**
Musculoskeletal and connective tissue disorders	
Rheumatoid Arthritis * 1	
# participants affected / at risk	**1/203 (0.49%)**
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Metastatic Neoplasm * 1	
# participants affected / at risk	**1/203 (0.49%)**
Psychiatric disorders	
Completed Suicide * 1	
# participants affected / at risk	**1/203 (0.49%)**
Respiratory, thoracic and mediastinal disorders	
Pulmonary Embolism * 1	
# participants affected / at risk	**1/203 (0.49%)**

* Events were collected by non-systematic assessment

1 Term from vocabulary, MedDRA 11.0

Other Adverse Events

Hide Other Adverse Events

Time Frame	All untoward events occurring between the time of obtaining informed consent through Week 30 or early termination were collected, regardless of causality.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Infliximab	Infliximab 3 mg/kg (intravenously) at weeks 0,2,6; Increase to 5 mg/kg (i.v.) or 7 mg/kg (i.v.) based on EULAR response

Other Adverse Events

	Infliximab
Total, other (not including serious) adverse events	
# participants affected / at risk	**54/203 (26.60%)**
Gastrointestinal disorders	
Nausea [*1]	
# participants affected / at risk	**11/203 (5.42%)**
Infections and infestations	
Sinusitis [*1]	
# participants affected / at risk	**17/203 (8.37%)**

Upper Respiratory Tract Infection * 1	
# participants affected / at risk	**14/203 (6.90%)**
Nervous system disorders	
Headache * 1	
# participants affected / at risk	**11/203 (5.42%)**
Respiratory, thoracic and mediastinal disorders	
Cough * 1	
# participants affected / at risk	**12/203 (5.91%)**

* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 11.0

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.
There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial

results after the trial is completed.

The agreement is:

- ☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.
- ☑ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.
- ☐ Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Sr. Director, Clinical Research - Medical Affairs
Organization: Centocor Ortho Biotech, Inc.
phone: 215-325-6811
e-mail: Ddeckto2@its.jnj.com

Responsible Party:	Centocor Ortho Biotech Services, L.L.C.
ClinicalTrials.gov Identifier:	NCT00714493 History of Changes
Obsolete Identifiers:	NCT01281449
Other Study ID Numbers:	**CR013879** C0168Z05 (Other Identifier: Centocor Ortho Biotech Services, L.L.C.)
Study First Received:	July 10, 2008
Results First Received:	January 14, 2011
Last Updated:	August 29, 2013
Health Authority:	United States: Food and Drug Administration

Disclaimer

Information in this posting shall not be considered to be a claim for any marketed product. Some information in this posting may differ from, or not be included in, the approved labeling for the product. Please refer to the full prescribing information for indications and proper use of the product.